{"url_path":"/sec/klrs/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1754068/0001193125-26-219328-index.html","accession_number":"0001193125-26-219328","cik":"0001754068","ticker":"KLRS","issuer_name":"Kalaris Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1754068/0001193125-26-219328-index.html","primary_entity_key":"0001754068","primary_entity_name":"Kalaris Therapeutics, Inc."},"word_count":83,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.\n\nWe did not sell any shares of our common stock, shares of our preferred stock or warrants to purchase shares of our stock, or grant any stock options, restricted stock units or restricted stock awards, during the period covered by this Quarterly Report on Form 10-Q that were not registered under the Securities Act of 1933, as amended and that have not otherwise been described in a Current Report on Form 8-K."}